Patents by Inventor Pablo Engel

Pablo Engel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant Fusion Proteins Targeting P-selectin, and Methods of Use Thereof for Treating Diseases and Disorders
    Publication number: 20240018247
    Abstract: The present invention describes compositions and methods for targeting complement inhibition to sites of p-selectin expression, and compositions for inhibiting p-selectin and complement.
    Type: Application
    Filed: August 30, 2023
    Publication date: January 18, 2024
    Inventors: Stephen Tomlinson, Ali Alawieh, Pablo Engel
  • Anti-C3d antibody conjugates and methods of detecting complement activation
    Patent number: 11191851
    Abstract: Provided herein, inter alia, are compositions and methods of using the same for detecting complement activation.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: December 7, 2021
    Assignee: MUSC Foundation for Research Development
    Inventors: Stephen Tomlinson, V. Michael Holers, Pablo Engel
  • Recombinant Fusion Proteins Targeting P-selectin, and Methods of Use Thereof for Treating Diseases and Disorders
    Publication number: 20210371534
    Abstract: The present invention describes compositions and methods for targeting complement inhibition to sites of p-selectin expression, and compositions for inhibiting p-selectin and complement.
    Type: Application
    Filed: June 1, 2021
    Publication date: December 2, 2021
    Inventors: Stephen Tomlinson, Ali Alawieh, Pablo Engel
  • Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
    Patent number: 5484892
    Abstract: The present invention is concerned with a series of novel monoclonal antibodies directed against CD22, a B lineage-restricted member of the Ig-superfamily which serves as an adhesion receptor expressed by mature B lymphocytes and is believed to function in the regulation of B cell activation. The monoclonal antibodies (mAb) specifically block red blood cell and leukocyte adhesion (80-100%) to COS cells transfected with CD22 cDNA and also identify a region of CD22 distinct from those defined by previously described CD22 mAb. The invention also encompasses therapeutic compositions including therapeutically effective amounts of a polypeptide comprising the CD22 ligand or portion thereof or of a polypeptide comprising the first two amino terminal Ig-like domains of CD22, or the ligand binding portion thereof. The antibodies and polypeptides of the invention find use in therapeutic methods for treatment of humans to retard or block CD22 adhesive function, particularly in autoimmune disease.
    Type: Grant
    Filed: May 21, 1993
    Date of Patent: January 16, 1996
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Thomas F. Tedder, Pablo Engel